» Articles » PMID: 24762560

A Randomized, Controlled Trial to Increase Discussion of Breast Cancer in Primary Care

Abstract

Background: Assessment and discussion of individual risk for breast cancer within the primary care setting are crucial to discussion of risk reduction and timely referral.

Methods: We conducted a randomized controlled trial of a multiethnic, multilingual sample of women ages 40 to 74 years from two primary care practices (one academic, one safety net) to test a breast cancer risk assessment and education intervention. Patients were randomly assigned to control or intervention group. All patients completed a baseline telephone survey and risk assessment (via telephone for controls, via tablet computer in clinic waiting room before visit for intervention). Intervention (BreastCARE) patients and their physicians received an individualized risk report to discuss during the visit. One-week follow-up telephone surveys with all patients assessed patient-physician discussion of family cancer history, personal breast cancer risk, high-risk clinics, and genetic counseling/testing.

Results: A total of 655 control and 580 intervention women completed the risk assessment and follow-up interview; 25% were high-risk by family history, Gail, or Breast Cancer Surveillance Consortium risk models. BreastCARE increased discussions of family cancer history [OR, 1.54; 95% confidence interval (CI), 1.25-1.91], personal breast cancer risk (OR, 4.15; 95% CI, 3.02-5.70), high-risk clinics (OR, 3.84; 95% CI, 2.13-6.95), and genetic counseling/testing (OR, 2.22; 95% CI, 1.34-3.68). Among high-risk women, all intervention effects were stronger.

Conclusions: An intervention combining an easy-to-use, quick risk assessment tool with patient-centered risk reports at the point of care can successfully promote discussion of breast cancer risk reduction between patients and primary care physicians, particularly for high-risk women.

Impact: Next steps include scaling and dissemination of BreastCARE with integration into electronic medical record systems.

Citing Articles

Use of web-based decision support to improve informed choice for chemoprevention: a qualitative analysis of pre-implementation interviews (SWOG S1904).

Michel A, Yi H, Amenta J, Collins N, Vaynrub A, Umakanth S BMC Med Inform Decis Mak. 2024; 24(1):272.

PMID: 39334347 PMC: 11430334. DOI: 10.1186/s12911-024-02691-0.


Making Informed Choices On Incorporating Chemoprevention into carE (MiCHOICE, SWOG 1904): Design and methods of a cluster randomized controlled trial.

Crew K, Anderson G, Arnold K, Stieb A, Amenta J, Collins N Contemp Clin Trials. 2024; 142:107564.

PMID: 38704119 PMC: 11180561. DOI: 10.1016/j.cct.2024.107564.


Risk-Stratified Breast Cancer Screening in Malaysia: Challenges and Opportunities.

Htay M, Su T, Donnelly M Asian Pac J Cancer Prev. 2024; 25(3):785-791.

PMID: 38546061 PMC: 11152396. DOI: 10.31557/APJCP.2024.25.3.785.


A Scoping Review of Personalized, Interactive, Web-Based Clinical Decision Tools Available for Breast Cancer Prevention and Screening in the United States.

Kamil D, Wojcik K, Smith L, Zhang J, Wilson O, Butera G MDM Policy Pract. 2024; 9(1):23814683241236511.

PMID: 38500600 PMC: 10946080. DOI: 10.1177/23814683241236511.


Decision aids for people facing health treatment or screening decisions.

Stacey D, Lewis K, Smith M, Carley M, Volk R, Douglas E Cochrane Database Syst Rev. 2024; 1:CD001431.

PMID: 38284415 PMC: 10823577. DOI: 10.1002/14651858.CD001431.pub6.


References
1.
Rebbeck T, Friebel T, Lynch H, Neuhausen S, van t Veer L, Garber J . Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004; 22(6):1055-62. DOI: 10.1200/JCO.2004.04.188. View

2.
Gail M, Brinton L, Byar D, Corle D, Green S, Schairer C . Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989; 81(24):1879-86. DOI: 10.1093/jnci/81.24.1879. View

3.
Chen S, Parmigiani G . Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007; 25(11):1329-33. PMC: 2267287. DOI: 10.1200/JCO.2006.09.1066. View

4.
Armstrong K, Quistberg D, Micco E, Domchek S, Guerra C . Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med. 2006; 166(20):2260-5. DOI: 10.1001/archinte.166.20.2260. View

5.
Hayflick S, Eiff M . Role of primary care providers in the delivery of genetics services. Community Genet. 2004; 1(1):18-22. DOI: 10.1159/000016131. View